Viragen

With global operations in the U.S. , Scotland and Sweden, Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon and monoclonal antibodies. Viragen's strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins. Viragen is publicly traded on the American Stock Exchange (VRA). Viragen's majority-owned subsidiary, Viragen International, Inc., is publicly traded on the Over-The-Counter Bulletin Board (VGNI). Viragen currently employs 62 people with corporate facilities in Plantation, Florida (Headquarters) and research and manufacturing facilities in Edinburgh, Scotland and Umeå, Sweden.

Contact Details: 865 SW 78th Avenue, Suite 100 Plantation FL 33324 United States of America Tel: (954) 233-8746 Fax: (954) 233-1414 Email: dcalder@viragen.com WWW: www.viragen.com/

Loading...

Press Releases on Viragen:
Oxford Biomedica Announces Appointment Of Chief Medical Officer	1st September, 2005	Oxford Biomedica	Oxford Biomedica Announces Appointment Of Chief Medical Officer Oxford, UK: 7 September 2005 – Oxford BioMedica (LSE:OXB.L), the
OXFORD BIOMEDICA SUCCESSFULLY COMPLETES STAGE ONE OF THE PHASE II TRIAL	1st August, 2005	Oxford Biomedica	OXFORD BIOMEDICA SUCCESSFULLY COMPLETES STAGE ONE OF THE PHASE II TRIAL WITH METXIA IN PANCREATIC CANCER Oxford, UK: 1 August 2005
Oxford Biomedica Is Granted Key Lentivector® Patents In China	1st July, 2005	Oxford Biomedica	Oxford Biomedica Is Granted Key Lentivector® Patents In China Oxford, UK: 4 July 2005 – Oxford BioMedica (LSE: OXB), the leading gene therapy company, announced today that the Patent
Oxford Biomedica Presents Encouraging Innurex Preclinical Efficacy Data	1st June, 2005	Oxford Biomedica	Oxford Biomedica Presents Encouraging Innurex Preclinical Efficacy Data In Spinal Cord Injury - Presentation at the 8th Annual Meeting of the American Society of Gene Therapy, 1-5
Oxford Biomedica Signs Lentivector® Licensing Agreement With Pfizer	1st June, 2005	Oxford Biomedica	Oxford Biomedica Signs Lentivector® Licensing Agreement With Pfizer Oxford, UK: 6 June 2005 – Oxford BioMedica (LSE: OXB), the leading gene therapy company, announced today that it has

Viragen Patents:
US Patent No.	Title
7259291	Enucleation of avian eggs by gamma irradiation
6433144	Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
6350589	Compositions of highly-purified natural mixtures of type I interferon derived from leukocytes and methods
5434249	Method for modulating specific activity of inteferon alpha
4435384	Transfer factor composition and skin treatment
→View more Viragen patents.

Viragen (VRA) Financial information Links from Barchart
VRA Quote from from Barchart.com
VRA Chart from from Barchart.com
VRA Profile from from Barchart.com
VRA Opinion from from Barchart.com
→View more Viragen finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 1728 times since April 2007, the link to the organisation's website has been followed 433 times

Recent Search Terms used to find this page: viragen interferon | viragen plantation | viragen | Oxford BioMedica Signs LentiVector Licensing Agreement with Pfizer | viragen interferon | Viragen plantation | Viragen International | vra quote | viragen vra | Viragen Plantation | .

Search for more companies in Plantation

Search for more companies in FL

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Viragen